A federal judge in Connecticut has declined to pause the multistate antitrust litigation accusing generic-drug manufacturers of price-fixing, even as settlement discussions continue. The decision keeps one of the most closely watched coordinated state enforcement actions on an active track, preserving litigation pressure while negotiations unfold in parallel.

The case is part of the long-running generic-drug pricing litigation brought by a coalition of state attorneys general against multiple manufacturers.

The antitrust challenge to Live Nation and Ticketmaster remains one of the most closely watched business cases in the country, even as reports indicate the U.S. Department of Justice reached a tentative settlement with the company in March 2026. The reason is straightforward: a broad coalition of states is still pressing forward, ensuring that the litigation continues to shape how courts, regulators, and the live-entertainment industry think about market power, vertical integration, and consumer harm.

The case, pending in the Southern District of New York as United States of America et al v. Live Nation Entertainment, Inc. et al, targets practices that have long drawn criticism from artists, venues, fans, and policymakers: ticketing fees, exclusive venue arrangements, and the combined influence that comes from operating both ticketing platforms and concert promotion businesses.